Core Insights - CG Oncology's BOND-003 study of cretostimogene monotherapy has been selected as a late breaker for the AUA's Practice-changing, Paradigm-shifting Clinical Trials in Urology, highlighting its potential impact on bladder cancer treatment [1] - The AUA Annual Meeting will take place from April 26-29, 2025, in Las Vegas, where CG Oncology will present various updates on ongoing clinical trials related to cretostimogene [1][7] Clinical Trial Presentations - The BOND-003 Cohort C study is a Phase 3, single-arm study focusing on high-risk BCG-unresponsive non-muscle invasive bladder cancer, with a presentation scheduled for April 26, 2025 [2] - An updated analysis from the BOND-003 and CORE-001 trials will be presented, focusing on translational correlates using urinary genomic disease burden [3] - Updates to the CORE-008 trial protocol will be discussed, which evaluates intravesical cretostimogene in patients with high-risk non-muscle invasive bladder cancer [3] Additional Studies - A multi-national, single-arm study of intravesical cretostimogene for high-risk, papillary only, BCG-unresponsive non-muscle invasive bladder cancer will also be presented [4] - The PIVOT-006 study, a Phase 3 randomized trial comparing adjuvant intravesical cretostimogene versus surveillance for intermediate-risk non-muscle invasive bladder cancer, will be discussed [5] Company Overview - CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapies for bladder cancer, aiming to improve the quality of life for patients [7]
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates